Lawrence S.
- Country
- France
- Department
- Hepato-Gastroenterology
Research Overview
- Phase 3 Randomized Double-Blind Placebo-Controlled Trial of Efruxifermin in Non-Cirrhotic NASH/MASH with Fibrosis
- Evaluation of Semaglutide in Patients with Non-Cirrhotic Non-Alcoholic Steatohepatitis and Fibrosis Stages 2 or 3: A Randomized, Placebo-Controlled Trial
- Phase 3 Multinational Study of Resmetirom in Non-Alcoholic Steatohepatitis Patients to Assess NASH Resolution and Fibrosis Progression Prevention
Data & Insights
Has run more than one trial at 112 of 206 partner sites.
Specializations
Liver Disease Management
The investigator specializes in treating advanced liver diseases, with particular emphasis on metabolic dysfunction-associated steatohepatitis (MASH) and non-alcoholic steatohepatitis (NASH).
- Hepatic Fibrosis Treatment
- Cirrhosis Management
- Steatohepatitis Therapeutics
Their work addresses both early-stage liver disease and compensated cirrhosis conditions.
Cholangitis & Hepatitis Care
Focuses on innovative treatments for primary sclerosing cholangitis and chronic hepatitis B, exploring novel therapeutic approaches for bile duct and liver inflammation.
- Cholestasis Treatment
- Hepatitis Management
- Bile Duct Disease Therapy
Specializes in managing chronic liver conditions requiring long-term therapeutic intervention.
Metabolic Liver Disease
Dedicated to treating metabolic dysfunction affecting liver health, with expertise in managing non-alcoholic fatty liver disease complications.
- Metabolic Disease Treatment
- Liver Function Enhancement
- Disease Progression Prevention
Explores therapeutic interventions for complex metabolic liver conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.